. . . "Metassalone"@en . . " "@en . "Metaxalone"@en . "Humans and other mammals"@en . . . . . . . . "Metaxalone is metabolized by the liver and excreted in the urine as unidentified metabolites."@en . . "Metaxalon"@en . "Metaxalone (marketed by King Pharmaceuticals under the brand name Skelaxin\u00AE) is a muscle relaxant used to relax muscles and relieve pain caused by strains, sprains, and other musculoskeletal conditions. Its exact mechanism of action is not known, but it may be due to general central nervous system depression. It is considered to be a moderately strong muscle relaxant, with relatively low incidence of side effects. Skelaxin comes in an 800 mg scored tablet. It previously came in both 400 mg and 800 mg tablets. The 400 mg tablet has been discontinued. Possible side effects include nausea, vomiting, drowsiness and CNS side effects such as dizziness, headache, and irritability."@en . . . "The absolute bioavailability of metaxalone from Skelaxin tablets is not known."@en . . . . . "Skelaxin"@en . "LD₅₀=775mg/kg (Rat, oral); LD₅₀=1690 mg/kg (Mouse, oral). When determining the LD₅₀ in rats and mice, progressive sedation, hypnosis and finally respiratoryfailure were noted as the dosage increased. In dogs, no LD₅₀ could be determined as the higher doses produced an emetic action in 15 to 30 minutes."@en . . . . . . . . "Metaxalona"@en . . . . . . . "approved"@en . "* 800 L"@en . . . . . . . . . . . "The mechanism of action of metaxalone in humans has not been established, but may be due to general central nervous system depression."@en . . . . . . . . . . . . . "1665-48-1"@en . . . . . . . . . . . . . . . . . "For the treatment of painful peripheral musculoskeletal conditions and spasticity from upper motor neuron syndromes."@en . . . . . . . . "Metaxalonum"@en . . . . "# See S, Ginzburg R: Choosing a skeletal muscle relaxant. Am Fam Physician. 2008 Aug 1;78(3):365-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18711953 # Elenbaas JK: Centrally acting oral skeletal muscle relaxants. Am J Hosp Pharm. 1980 Oct;37(10):1313-23. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/6999895"@en . . . . "* 68 +/- 50 L/h [Subjects received 1\u00D7400mg tablet under fasted conditions] * 66 +/- 51 L/h [Subjects received 2\u00D7400 mg tablets under fasted conditions]"@en . . . . "9.2 (+/- 4.8) hours"@en . . "Spiridon Spireas, \"Bioavailable compositions of metaxalone and processes for producing the same.\" U.S. Patent US20050276844, issued December 15, 2005."@en .